Bristol Myers Squibb said Zenbexus, which received FDA accelerated approval for multiple myeloma, cut the risk of disease progression by 51% versus standard therapy in a Phase 3 trial. The company positioned the result as a step forward for patients needing improved control of progressive disease. While accelerated approval underscores the FDA’s willingness to use earlier efficacy signals, investors will likely focus next on how durable benefit holds up as data mature and whether endpoints move from progression risk toward longer-term survival outcomes.